Bevacizumab/Irinotecan. An active treatment for recurrent high grade gliomas: Preliminary results of an ANOCEF Multicenter Study;Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d'une étude multicentrique de l'Anocef

Revue Neurologique

Volumn 164, Issue 6-7, 2008, Pages 588-594

  Guiu, S ^a   Taillibert, S ^b   Chinot, O ^c   Taillandier, L ^d   Honnorat, J ^e   Dietrich, P Y ^f   Maire, J P ^g   Guillamo, J S ^h   Guiu, B ⁱ   Catry Thomas, I ^g   Capelle, F ^b   Thiebaut, A ^c   Cartalat Carel, S ^g   Deville, C ^j   Fumoleau, P ^a   Desjardins, A ^k   Xuan, K Hoang ^b   Chauffert, B ^a  

^a Centre de Lutte Contre le Cancer GF Leclerc   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c TIMONE HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e HÔPITAL NEUROLOGIQUE   (France)

^f Laboratory of Molecular Embryology   (Switzerland)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h CHU CÔTE DE NACRE   (France)

ⁱ HÔPITAL DU BOCAGE   (France)

^j Unité d'épidémiologie et de biostatistiques   (France)

^k DUKE UNIVERSITY   (United States)

more..

Author keywords

Bevacizumab; Glioblastoma; High grade glioma; Irinotecan

Indexed keywords

BEVACIZUMAB; IRINOTECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLIOMA; HEART INFARCTION; HEMATURIA; HUMAN; LEUKOENCEPHALOPATHY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; THROMBOEMBOLISM; THROMBOPHLEBITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CHILD, PRESCHOOL; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES;

EID: 46149123043     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2008.04.003     Document Type: Article

References (33)

1. Allen J.A., Adlakha A., and Bergethon P.R. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 63 (2006) 1475-1478
2. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
3. Batchelor T.T., Gilbert M.R., Supko J.G., Carson K.A., Nabors L.B., Grossman S.A., et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro. Oncol. 6 (2004) 21-27
4. Buckner J.C. Factors influencing survival in high-grade gliomas. Semin Oncol 30 6 Suppl. 19 (2003) 10-14
5. Chang S.M., Theodosopoulos P., Lamborn K., Malec M., Rabbitt J., Page M., et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer 100 (2004) 605-611
6. Cloughesy T. (2007). Communication orale. Society of Neuro-Oncology, Dallas, novembre 2007.
7. Friedland DM, Ali S A, Ahmad A, Rahman M, Bejjani G, Braffet M. (2007). Bevacizumab plus irinotecan therapy in relapsed, heavily pre-treated malignant glioma: a case series. ASCO Annual Meeting, Chicago.
8. Friedman H.S., Petros W.P., Friedman A.H., Schaaf L.J., Kerby T., Lawyer J., et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17 (1999) 1516-1525
9. Godard S., Getz G., Delorenzi M., Farmer P., Kobayashi H., Desbaillets I., et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63 (2003) 6613-6625
10. Goli KJ, Desjardins A, Herndon II JE, Rich JN, Reardon DA, et al. (2007). Phase 2 trial of bevacizumab and irinotecan in the treatment of malignant gliomas. ASCO Annual Meeting, Chicago.
11. Gorlia T., van den Bent M.J., Hegi M.E., Mirimanoff R.O., Weller M., Cairncross J.G., et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9 (2008) 29-38
12. Eastern Cooperative Oncology Group Trial 2394, Grossman S.A., O'Neill A., Grunnet M., Mehta M., Pearlman J.L., Wagner H., et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme. J Clin Oncol 21 (2003) 1485-1491
13. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
14. Kang T, Jin T, Peereboom D. (2007). Irinotecan and bevacizumab in progressive primary brain tumors: the Cleveland Clinic experience. ASCO Annual Meeting, Chicago.
15. Lamszus K., Ulbricht U., Matschke J., Brockmann M.A., Fillbrandt R., and Westphal M. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9 (2003) 1399-1405
16. Lassen U, Grunnet K, Kosteljanetz M, Hasselbalch B, Laursen H, Poulsen HS. (2007). Bevacizumab, a monoclonal antibody to the vascular endothelial growth factor (VEGF), and irinotecan for treatment of recurrent primary malignant brain tumors in adults. ASCO Annual Meeting, Chicago.
17. Macdonald D.R., Cascino T.L., Schold Jr. S.C., and Cairncross J.G. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 (1990) 1277-1280
18. Miller K.D. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3 (2003) 421-422
19. Mirimanoff R.O., Gorlia T., Mason W., Van den Bent M.J., Kortmann R.D., Fisher B., et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24 (2006) 2563-2569
20. Narayana A, Chheang S, Knopp E, Peccerelli N, Babb J, Johnson G, et al. (2007). Comparing cerebral blood volume and vascular permeability measurements with tumor volume measurements following anti-angiogenesis therapy in recurrent gliomas. ASCO Annual Meeting, Chicago.
21. Ozcan C., Wong S.J., and Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354 (2006) 980-982 discussion 980-982
22. Prados M.D., Lamborn K., Yung W.K., Jaeckle K., Robins H.I., Mehta M., et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8 (2006) 189-193
23. Raval S, Hwang S, Dorsett L. (2007). Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM). ASCO Annual Meeting, Chicago.
24. Sathornsumetee S., and Rich J.N. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 13 (2007) 3545-3558
25. Stark-Vance V. (2005). Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. World Federation of Neuro-oncology Meeting.
26. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
27. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64 11 (2004) 3731-3736
28. Vredenburgh J.J., Desjardins A., Herndon II J.E., Dowell J.M., Reardon D.A., Quinn J.A., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 (2007) 1253-1259
29. Vredenburgh J.J., Desjardins A., Herndon II J.E., Marcello J., Reardon D.A., Quinn J.A., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 (2007) 4722-4729
30. Weathers A, Paleologos N. (2007). Reversible posterior leukoencephalopathy syndrome in a patient treated with bevacizumab and irinotecan. Twelfth Annual Meeting of the Society for Neuro-Oncology, Lake Las Vegas.
31. Weis S.M., and Cheresh D.A. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437 (2005) 497-504
32. Wong E.T., Hess K.R., Gleason M.J., Jaeckle K.A., Kyritsis A.P., Prados M.D., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17 (1999) 2572-2578
33. Yung W.K., Albright R.E., Olson J., Fredericks R., Fink K., Prados M.D., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 (2000) 588-593